These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25956695)

  • 1. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
    Kim TH; Jeong JW; Song JH; Lee KR; Ahn S; Ahn SH; Kim S; Koo TS
    Arch Pharm Res; 2015 Nov; 38(11):2076-82. PubMed ID: 25956695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
    Lee KR; Jeong JW; Hyun HC; Jang E; Ahn S; Choi S; Joo SH; Kim S; Koo TS
    Xenobiotica; 2018 Aug; 48(8):831-838. PubMed ID: 28803538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
    Lee KR; Chae YJ; Koo TS
    Xenobiotica; 2011 Dec; 41(12):1100-7. PubMed ID: 21838595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetic Studies of Enzalutamide.
    Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
    Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Ma H; Xu W; Ni J; Zhao N; Tang S; Li S; Cai T; Xiu J; Kang X; Gao S; Zhang L; Zhou T
    Prostate; 2022 Feb; 82(2):276-285. PubMed ID: 34807458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.
    Ohtsu Y; Gibbons JA; Suzuki K; Fitzsimmons ME; Nozawa K; Arai H
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):611-626. PubMed ID: 27590197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic characterization of the novel TAZ modulator TM-25659 using a multicompartment kinetic model in rats and a possibility of its drug-drug interactions in humans.
    Lee KR; Choi SH; Song JS; Kwak EY; Chae YJ; Im SH; Lee BH; Seo H; Cho WK; Kim MS; Kim NJ; Ahn SH; Bae MA
    Xenobiotica; 2013 Feb; 43(2):193-200. PubMed ID: 22856387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
    Stüben J; Port R; Bertram B; Bollow U; Hull WE; Schaper M; Pohl J; Wiessler M
    Cancer Chemother Pharmacol; 1996; 38(4):355-65. PubMed ID: 8674159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
    Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
    J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of verproside after intravenous and oral administration in rats.
    Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
    Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.
    Shin BS; Hong SH; Bulitta JB; Hwang SW; Kim HJ; Lee JB; Yang SD; Kim JE; Yoon HS; Kim DJ; Yoo SD
    J Toxicol Environ Health A; 2009; 72(21-22):1406-11. PubMed ID: 20077212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
    Hu ZY; Li XX; Du FF; Yang JL; Niu W; Xu F; Wang FQ; Li C; Sun Y
    Acta Pharmacol Sin; 2013 Nov; 34(11):1437-48. PubMed ID: 24056706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.
    Koo TS; Kim SJ; Ha DJ; Baek M; Moon H
    Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
    Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
    Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide.
    Jiang J; Pang X; Li L; Dai X; Diao X; Chen X; Zhong D; Wang Y; Chen Y
    Drug Des Devel Ther; 2016; 10():2181-91. PubMed ID: 27462143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
    Frick LW; St John L; Taylor LC; Painter GR; Furman PA; Liotta DC; Furfine ES; Nelson DJ
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2285-92. PubMed ID: 8285607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.